TIDMERGO

RNS Number : 5393O

Ergomed plc

10 February 2021

PRESS RELEASE

Notice of Preliminary Results

Guildford, UK - 10 February 2021: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its preliminary results for the year ending 31 December 2020 on 23 March 2021.

Miroslav Reljanović, Executive Chairman, and Richard Barfield, Chief Financial Officer, will host a virtual presentation and conference call for analysts at 9.00am GMT on the day of the results.

ENDS

Enquiries:

 
 Ergomed plc                                           Tel: +44 (0) 1483 402 
                                                                         975 
 Miroslav Reljanović (Executive Chairman) 
 Richard Barfield (Chief Financial Officer) 
 
 Numis Securities Limited                          Tel: +44 (0) 20 7260 1000 
 Freddie Barnfield / Huw Jeremy (Nominated 
  Adviser) 
 James Black (Broker) 
 
 Consilium Strategic Communications - for          Tel: +44 (0) 20 3709 5700 
  UK enquiries 
 Chris Gardner / Sue Stuart                      ergomed@consilium-comms.com 
 Matthew Neal / Olivia Manser

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORTLMBTMTJMTIB

(END) Dow Jones Newswires

February 10, 2021 02:00 ET (07:00 GMT)

Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Ergomed.
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Ergomed.